Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status.

bleeding factor IX factor VIII hemophilia phenotype

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 19 09 2022
revised: 10 12 2022
accepted: 17 12 2022
entrez: 13 3 2023
pubmed: 14 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

Although the phenotype of severe hemophilia has been well studied, there are still knowledge gaps in nonsevere hemophilia. The objective of this study was to characterize the clinical bleeding phenotype in nonsevere hemophilia and its association with different factor VIII/IX assessments. This was a cross-sectional, multicenter study to investigate the bleeding phenotype in adults with nonsevere hemophilia by the number of bleeding and joint bleeding in the past 5 years, a joint score, and the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT). Factor levels were analyzed by 1-stage (lowest in history and at study inclusion) and chromogenic assay (at study inclusion). Patients were enrolled between March 2015 and May 2019. Of the 111 patients (86 with mild and 25 with moderate hemophilia), 57 patients (54.8%) reported any bleeding and 24 (23.1%) any joint bleeding in the past 5 years. A joint score ≥1 was found in 44 patients (41.9%), an ISTH-BAT ≥4 in 100 patients (90.1%), and an ISTH-BAT joint item ≥1 in 50 patients (45.0%). Within the ISTH-BAT, muscle and joint bleeds showed the largest difference between mild and moderate hemophilia. The lowest factor VIII/IX level in patients' history was best associated with bleeding outcomes. Factor was inversely associated with joint bleeds (incidence rate ratio 0.88; 95% CI, 0.79-0.98), joint score, and ISTH-BAT (odds ratios from proportional odds ordinal logistic regression 0.92; 95% CI, 0.87-0.97; and 0.89; 95% CI, 0.86-0.93, respectively). The occurrence of joint bleeding differentiated persons with mild and moderate hemophilia. The ISTH-BAT and lowest factor in patients' history provided valuable information of the bleeding phenotype in nonsevere hemophilia.

Sections du résumé

Background UNASSIGNED
Although the phenotype of severe hemophilia has been well studied, there are still knowledge gaps in nonsevere hemophilia.
Objectives UNASSIGNED
The objective of this study was to characterize the clinical bleeding phenotype in nonsevere hemophilia and its association with different factor VIII/IX assessments.
Methods UNASSIGNED
This was a cross-sectional, multicenter study to investigate the bleeding phenotype in adults with nonsevere hemophilia by the number of bleeding and joint bleeding in the past 5 years, a joint score, and the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT). Factor levels were analyzed by 1-stage (lowest in history and at study inclusion) and chromogenic assay (at study inclusion). Patients were enrolled between March 2015 and May 2019.
Results UNASSIGNED
Of the 111 patients (86 with mild and 25 with moderate hemophilia), 57 patients (54.8%) reported any bleeding and 24 (23.1%) any joint bleeding in the past 5 years. A joint score ≥1 was found in 44 patients (41.9%), an ISTH-BAT ≥4 in 100 patients (90.1%), and an ISTH-BAT joint item ≥1 in 50 patients (45.0%). Within the ISTH-BAT, muscle and joint bleeds showed the largest difference between mild and moderate hemophilia. The lowest factor VIII/IX level in patients' history was best associated with bleeding outcomes. Factor was inversely associated with joint bleeds (incidence rate ratio 0.88; 95% CI, 0.79-0.98), joint score, and ISTH-BAT (odds ratios from proportional odds ordinal logistic regression 0.92; 95% CI, 0.87-0.97; and 0.89; 95% CI, 0.86-0.93, respectively).
Conclusion UNASSIGNED
The occurrence of joint bleeding differentiated persons with mild and moderate hemophilia. The ISTH-BAT and lowest factor in patients' history provided valuable information of the bleeding phenotype in nonsevere hemophilia.

Identifiants

pubmed: 36908769
doi: 10.1016/j.rpth.2023.100047
pii: S2475-0379(23)00012-2
pmc: PMC9999231
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100047

Informations de copyright

© 2023 The Authors.

Références

Haemophilia. 2017 Jul;23(4):620-627
pubmed: 28440032
Haemophilia. 2009 Jan;15(1):83-90
pubmed: 18713246
J Thromb Haemost. 2020 May;18(5):1081-1086
pubmed: 32073230
Rheumatol Int. 2007 Mar;27(5):501-2
pubmed: 17047956
Thromb Haemost. 2000 Dec;84(6):977-80
pubmed: 11154144
Haemophilia. 2018 May;24(3):405-413
pubmed: 29388750
Haemophilia. 2013 Jul;19(4):595-601
pubmed: 23534856
Haemophilia. 2014 Nov;20(6):831-5
pubmed: 25196510
Transfus Apher Sci. 2018 Aug;57(4):556-560
pubmed: 29921547
Hamostaseologie. 2019 Aug;39(3):284-293
pubmed: 30419589
Haemophilia. 2005 Jan;11(1):43-8
pubmed: 15660988
Haemophilia. 2011 Jan;17(1):41-4
pubmed: 20825504
J Thromb Haemost. 2018 Oct;16(10):2106-2110
pubmed: 30182468
Blood Adv. 2022 Jul 26;6(14):4256-4265
pubmed: 35533261
Haemophilia. 2021 Jan;27 Suppl 1:17-24
pubmed: 32870546
Int J Lab Hematol. 2018 Apr;40(2):175-180
pubmed: 29115727
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
J Pain. 2016 Sep;17(9 Suppl):T21-49
pubmed: 27586830
Haemophilia. 2008 Sep;14(5):1049-54
pubmed: 18540892
J Thromb Haemost. 2010 Sep;8(9):2063-5
pubmed: 20626619
Haemophilia. 2016 Nov;22(6):912-918
pubmed: 27868369
Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):902-6
pubmed: 10764652
Thromb Haemost. 2013 Jun;109(6):1170-9
pubmed: 23571706
Semin Hematol. 1993 Jul;30(3 Suppl 2):3-6
pubmed: 8367740
Thromb Res. 2022 Mar;211:19-26
pubmed: 35063801
J Thromb Haemost. 2010 Mar;8(3):421-32
pubmed: 19995408
Haemophilia. 2011 Nov;17(6):849-53
pubmed: 21545376
Blood Transfus. 2014 Jan;12 Suppl 1:s330-6
pubmed: 23245711
Wien Klin Wochenschr. 2009;121(5-6):196-201
pubmed: 19412749
J Thromb Haemost. 2018 Jan;16(1):125-130
pubmed: 29064634
Haemophilia. 2019 Jan;25(1):e1-e10
pubmed: 30427100
J Thromb Haemost. 2011 Mar;9(3):524-30
pubmed: 21166991
Haemophilia. 2014 Jul;20(4):550-8
pubmed: 24517184
J Thromb Haemost. 2014 Nov;12(11):1935-9
pubmed: 25059285
J Thromb Haemost. 2016 Feb;14(2):248-61
pubmed: 26663865
J Thromb Haemost. 2022 May;20(5):1126-1137
pubmed: 35171522

Auteurs

Judit Rejtő (J)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Daniel Kraemmer (D)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Ella Grilz (E)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Oliver Königsbrügge (O)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Cornelia Gabler (C)

IT Systems and Communications, Medical University of Vienna, Vienna, Austria.

Gerhard Schuster (G)

Red Cross Blood Service Linz, Linz, Austria.

Clemens Feistritzer (C)

Department of Internal Medicine V - Haematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.

Raute Sunder-Plaßmann (R)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Peter Quehenberger (P)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Cihan Ay (C)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Ingrid Pabinger (I)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Johanna Gebhart (J)

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Classifications MeSH